Former Chairman of Spectranetics Corporation;
NACD 2018 Director of the Year
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:REPR) (“RMS
Medical”) today announced that R. John Fletcher has been appointed
as an independent member of RMS Medical’s Board of Directors. With this
appointment, RMS Medical’s Board of Directors fills the vacancy created
by the passing of Arthur J. Radin.
Mr. Fletcher brings more than 35 years of healthcare and medical device
experience to RMS Medical. He currently serves as CEO and Managing
Director of Fletcher Spaght Inc., a strategy consulting and venture
capital firm which he founded in 1983. Prior to founding Fletcher
Spaght, he was Senior Manager at The Boston Consulting Group, advising a
broad range of companies in healthcare and high technology industries.
Mr. Fletcher joined the Board of Directors of publicly-traded medical
device company Spectranetics Corporation in 2002 and served as Chairman
of the Board from 2010-2017. During his 15-year tenure as a member of
the board, Spectranetics expanded its therapeutic platforms and
generated significant commercial growth. In August 2017 Spectranetics
was acquired by Royal Philips in a transaction valued at $2.2 billion.
Mr. Fletcher was named 2018 Director of the Year by The National
Association of Corporate Directors (NACD) for his work at Spectranetics.
Mr. Fletcher currently serves on the Board of Directors of Axcelis
Corporation, MRI Interventions and is Chairman of Metabolon. He is
Chairman Emeritus of the Corporate Collaboration Council at the Thayer
School of Engineering/Tuck School of Business at Dartmouth College and
serves on the Board of Advisors of Beth Israel Deaconess Medical Center
and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from
Southern Illinois University and a BBA in Marketing from George
Washington University. He was an Instructor for courses in international
business and a Ph.D. Candidate at the Wharton School of the University
of Pennsylvania. Mr. Fletcher served as a Captain and jet pilot in the
United States Air Force.
“John’s vision and leadership in the medical device industry has helped
improve the lives of patients around the world,” said Don Pettigrew,
President and CEO of RMS Medical. “We believe he will be a significant
asset as we continue to expand RMS Medical’s business and elevate our
industry profile.”
“John is an industry veteran and brings to RMS Medical a proven record
of building brands, teams and businesses, and advising growth-oriented
public companies in the healthcare industry,” said Daniel S. Goldberger,
Executive Chairman of RMS Medical. “I am thrilled and excited to welcome
him to our board.”
“It’s an exciting time at RMS Medical and I am very pleased to join the
Board of Directors,” said Mr. Fletcher. “The infusion therapy market is
growing and I believe RMS Medical, with its portfolio of reliable,
easy-to-use, and effective products, is well-positioned to participate
in this anticipated industry growth.”
David W. Anderson Named Audit Committee Chair
RMS Medical also announced that David W. Anderson has been appointed
Chairman of the Audit Committee. Mr. Anderson succeeds Arthur J. Radin.
A member of the Board of Directors since 2016, Mr. Anderson is a
seasoned healthcare executive with more than 23 years of experience in
the medical device industry.
“David is a valued board member with a distinguished background in the
healthcare industry, and we welcome him to his new position,” said Mr.
Goldberger.
John Fletcher will join the Audit Committee with David Anderson and
Robert Allen.
About RMS Medical Products
RMS Medical develops, manufactures and commercializes innovative and
easy-to-use specialty infusion solutions that improve quality of life
for patients around the world. The FREEDOM Syringe Infusion System
currently includes the FREEDOM60® and FreedomEdge®
Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and
RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices
are used for infusions administered in the home and alternate care
settings. For more information about RMS Medical, please visit www.rmsmedicalproducts.com.
Forward-Looking Statements
The statements contained herein include prospects, statements of future
expectations and other forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are based on
management's current views and assumptions and involve known and unknown
risks and uncertainties, identified by words such as "believe" and
''will''. Actual results, performance or events may differ materially
from those expressed or implied in such forward-looking statements.
Factors that may cause actual results to differ materially from current
expectations and other risks are discussed in RMS Medical’s filings with
the U.S. Securities and Exchange Commission, including its Annual Report
on Form 10-K, which filings are available from the SEC and RMS Medical’s
website. RMS Medical undertakes no obligation to update any
forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005104/en/
Copyright Business Wire 2019